Page last updated: 2024-10-21

pk 11195 and Central Nervous System Disease

pk 11195 has been researched along with Central Nervous System Disease in 2 studies

PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Scarf, AM1
Ittner, LM1
Kassiou, M1
Visigalli, I1
Moresco, RM1
Belloli, S1
Politi, LS1
Gritti, A1
Ungaro, D1
Matarrese, M1
Turolla, E1
Falini, A1
Scotti, G1
Naldini, L1
Fazio, F1
Biffi, A1

Reviews

1 review available for pk 11195 and Central Nervous System Disease

ArticleYear
The translocator protein (18 kDa): central nervous system disease and drug design.
    Journal of medicinal chemistry, 2009, Feb-12, Volume: 52, Issue:3

    Topics: Acetamides; Apoptosis; Central Nervous System; Central Nervous System Diseases; Drug Design; Humans;

2009

Other Studies

1 other study available for pk 11195 and Central Nervous System Disease

ArticleYear
Monitoring disease evolution and treatment response in lysosomal disorders by the peripheral benzodiazepine receptor ligand PK11195.
    Neurobiology of disease, 2009, Volume: 34, Issue:1

    Topics: Animals; Brain; Carbon Radioisotopes; Central Nervous System Diseases; Demyelinating Diseases; Disea

2009